Free Trial
Fall Lock-In Sale! MarketBeat All Access, $149 a Year for Life
Lock In $149
Claim MarketBeat All Access Sale Promotion

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Equillium, Inc. stock logo
EQ
Equillium
$1.21
-1.5%		$1.86
$0.76
▼
$3.54
$77.04M1.93622,768 shs34,530 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.58
-7.1%		$2.65
$1.47
▼
$25.05
$1.55M2.08134,200 shs16,599 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shsN/A
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Equillium, Inc. stock logo
EQ
Equillium
0.00%+3.36%-26.35%-50.00%-12.77%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%-28.24%-29.14%-65.85%-92.91%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%-89.90%-98.00%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Equillium, Inc. stock logo
EQ
Equillium
$1.21
-1.5%		$1.86
$0.76
▼
$3.54
$77.04M1.93622,768 shs34,530 shs
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.58
-7.1%		$2.65
$1.47
▼
$25.05
$1.55M2.08134,200 shs16,599 shs
ObsEva SA stock logo
OBSV
ObsEva
$0.00
$0.08
▼
$2.14
$7.94M0.688.94 million shsN/A
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven.

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Equillium, Inc. stock logo
EQ
Equillium
0.00%+3.36%-26.35%-50.00%-12.77%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00%-28.24%-29.14%-65.85%-92.91%
ObsEva SA stock logo
OBSV
ObsEva
0.00%0.00%0.00%-89.90%-98.00%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Equillium, Inc. stock logo
EQ
Equillium
2.91
Moderate Buy$7.57524.71% Upside
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
0.00
N/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest MTNB, EQ, and OBSV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/12/2026
Equillium, Inc. stock logo
EQ
Equillium
Leerink Partners logo
Leerink Partners
Subscribe to MarketBeat All Access to unlock brokerage rankings
Initiated CoverageOutperform$6.00
9/21/2026
Equillium, Inc. stock logo
EQ
Equillium
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (D-)
9/4/2026
Equillium, Inc. stock logo
EQ
Equillium
Roth Capital logo
Roth Capital
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$12.00
8/11/2026
Equillium, Inc. stock logo
EQ
Equillium
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong Sell ➝ Hold
(Data available from 10/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Equillium, Inc. stock logo
EQ
Equillium
$41.10M1.87N/AN/A$0.47 per share2.58
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
$1.10M1.41N/AN/A$11.30 per share0.14
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/A$0.41 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Equillium, Inc. stock logo
EQ
Equillium
-$22.40M-$0.20N/AN/AN/AN/A-41.15%-38.29%11/12/2026 (Estimated)
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
-$10.35M-$3.89N/AN/AN/AN/A-166.11%-102.20%N/A
ObsEva SA stock logo
OBSV
ObsEva
-$58.38M-$0.92N/AN/AN/AN/A-416.36%-92.01%N/A

Latest MTNB, EQ, and OBSV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/12/2026Q3 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.05N/AN/AN/AN/AN/A
8/13/2026Q2 2026
Equillium, Inc. stock logo
EQ
Equillium
-$0.0540-$0.04+$0.0140-$0.04N/AN/A
8/13/2026Q2 2026
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A-$3.15N/A-$3.15N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Equillium, Inc. stock logo
EQ
Equillium
N/AN/AN/AN/AN/A
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/AN/AN/AN/AN/A
ObsEva SA stock logo
OBSV
ObsEva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Equillium, Inc. stock logo
EQ
Equillium
N/A
23.40
23.40
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
N/A
0.85
0.85
ObsEva SA stock logo
OBSV
ObsEva
N/A
0.61
0.61

Institutional Ownership

CompanyInstitutional Ownership
Equillium, Inc. stock logo
EQ
Equillium
27.05%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
11.77%
ObsEva SA stock logo
OBSV
ObsEva
17.52%

Insider Ownership

CompanyInsider Ownership
Equillium, Inc. stock logo
EQ
Equillium
17.84%
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
4.60%
ObsEva SA stock logo
OBSV
ObsEva
14.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Equillium, Inc. stock logo
EQ
Equillium
1463.41 million52.10 millionOptionable
Matinas Biopharma Holdings, Inc. stock logo
MTNB
Matinas Biopharma
2980,000935,000N/A
ObsEva SA stock logo
OBSV
ObsEva
5077.97 million66.74 millionNot Optionable

Recent News About These Companies

ObsEva files uterine fibroid drug in US, chasing AbbVie, Myovant
August 31, 2024  |  pharmaphorum.comP
ObsEva SA OBSN
November 11, 2023  |  morningstar.comM
ObsEva SA OBSEF
November 11, 2023  |  morningstar.comM
ObsEva (NASDAQ: OBSV)
June 18, 2023  |  fool.comhttps://www.fool.com/quote/nasdaq/obsv/
Tocolytic Agents Market to a Steady Revenue CAGR of 5.3% by ... - InvestorsObserver
May 10, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - Yahoo Finance
May 2, 2023  |  news.google.comN
ObsEva Says Fabien De Ladonchamps Is New CEO - Nasdaq
May 2, 2023  |  news.google.comN
ObsEva Appoints Fabien de Ladonchamps as Chief Executive Officer - GlobeNewswire
May 2, 2023  |  news.google.comN
Gameto Appoints Teri Loxam as Chief Financial Officer - citybiz
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Marketscreener.com
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Yahoo Finance
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - Benzinga
April 28, 2023  |  news.google.comN
ObsEva Annual Report 2022 - EIN News
April 28, 2023  |  news.google.comN
Gameto Expands Executive Team with the Addition of Teri Loxam as ... - PR Newswire
April 28, 2023  |  news.google.comN
Endometriosis Market to Hit USD 3.9 Bn by 2029: Competitive ... - Digital Journal
April 26, 2023  |  news.google.comN
Endometriosis Pain Pipeline Insight, Emerging Therapies, Key Players, and Clinical Stages - openPR
April 23, 2023  |  news.google.comN
ObsEva to Suspend Reporting With SEC Following Delisting From Nasdaq - Marketscreener.com
April 21, 2023  |  news.google.comN
ObsEva Announces Change of Central Securities Depositary - Yahoo Finance
April 20, 2023  |  news.google.comN
ObsEva Announces Change of Central Securities Depositary - GlobeNewswire
April 20, 2023  |  news.google.comN
Tackling Reproductive Health and Fertility Care - Pharmaceutical Executive
April 13, 2023  |  news.google.comN

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Glass-walled office building lobby at sunset with a city skyline reflected in the exterior facade.
Data Centers Got the AI Hype—But Office REITs May Get the Rent Hikes
By Chris Markoch | September 27, 2026
ASML logo on a semiconductor lithography machine with a robotic arm handling silicon wafers in a cleanroom.
ASML Can’t Keep Up With AI Demand—Why That's a Good Thing
By Thomas Hughes | October 15, 2026
Akamai logo displayed in a data center aisle lined with illuminated server racks.
Akamai’s Anthropic Deal Puts $5.5 Billion Behind Its Edge AI Pivot
By Jeffrey Neal Johnson | September 28, 2026
Plexus logo displayed over an electronics manufacturing facility with a circuit board assembly machine and technician in the background.
Plexus Is Booming—But Can the Growth Story Last?
By Peter Frank | October 3, 2026
First Citizens BancShares Looks Like the Cleaner Deregulation Bet Than MP Materials
First Citizens BancShares vs MP Materials: A Tale of 2 Regulation Bets
By Bridget Bennett | October 5, 2026
Equillium stock logo

Equillium NASDAQ:EQ

$1.21 -0.02 (-1.46%)
As of 10:25 AM Eastern
This is a fair market value price provided by Massive. Learn more.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Matinas Biopharma stock logo

Matinas Biopharma NYSEAMERICAN:MTNB

$1.58 -0.12 (-7.09%)
As of 09:37 AM Eastern

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

ObsEva stock logo

ObsEva NASDAQ:OBSV

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women's reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas